0001817048-20-000004.txt : 20200915 0001817048-20-000004.hdr.sgml : 20200915 20200914210941 ACCESSION NUMBER: 0001817048-20-000004 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20200915 DATE AS OF CHANGE: 20200914 EFFECTIVENESS DATE: 20200915 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Gilgamesh Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001817048 IRS NUMBER: 842552195 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-374502 FILM NUMBER: 201174531 BUSINESS ADDRESS: STREET 1: 201 DAM TRAIL #1349 CITY: LINVILLE STATE: NC ZIP: 28646 BUSINESS PHONE: 347-967-6831 MAIL ADDRESS: STREET 1: 201 DAM TRAIL #1349 CITY: LINVILLE STATE: NC ZIP: 28646 D/A 1 primary_doc.xml X0708 D/A LIVE 0001817048 Gilgamesh Pharmaceuticals, Inc. 113 University Place Suite 1019 New York NY NEW YORK 10003 3479676831 DELAWARE None None Corporation true 2019 Jonathan Sporn 113 University Place Suite 1019 New York NY NEW YORK 10003 Executive Officer Director Andrew Kruegel 113 University Place Suite 1019 New York NY NEW YORK 10003 Director Dalibor Sames 113 University Place Suite 1019 New York NY NEW YORK 10003 Director Pharmaceuticals Decline to Disclose 06b true 0001817048-20-000002 2020-09-09 false true Simple Agreement for Future Equity (SAFE), the equity securities of Issuer into which the SAFE may convert (Converted Securities), and the equity securities of Issuer into which the Converted Securities may convert. false 10000 Indefinite 735000 Indefinite false 10 0 0 0 true Some of the proceeds may be used to compensate (in the form of salary) officers and directors who provide services to the issuer. false Gilgamesh Pharmaceuticals, Inc. Jonathan Sporn, M.D. /s/ Jonathan Sporn President and Chief Executive Officer 2020-09-14